ISRG
Intuitive Surgical, Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
56.21
PEG
2.45
P/B
9.00
P/S
15.95
EV/EBITDA
43.47
DCF Value
$104.66
FCF Yield
1.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
66.0%
Operating Margin
29.3%
Net Margin
28.4%
ROE
16.4%
ROA
14.1%
ROIC
13.7%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $2.87B | $794.8M | $2.21 |
| FY 2025 | $10.06B | $2.86B | $7.87 |
| Q3 2025 | $2.51B | $704.4M | $1.95 |
| Q2 2025 | $2.44B | $658.4M | $1.81 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllLatest News
Company Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
1.68
Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System to enable complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung. It also provides a suite of stapling, energy, and core instrumentation for its surgical systems; progressive learning pathways to support the use of its technology; a complement of services to its customers, including support, installation, repair, and maintenance; and integrated digital capabilities providing unified and connected offerings, streamlining performance for hospitals with program-enhancing insights. The company was incorporated in 1995 and is headquartered in Sunnyvale, California.